Cell BioEngines Secures an Additional $2 Million in Funding From SOSV and the Empire State Development’s New York Ventures
July 20 2024 - 4:11PM
Cell BioEngines, Inc., a New York, USA-based company researching
stem cells in order to develop new cell therapies unlocked $1.75
million additional funds from SOSV and the Partnership Fund through
the new therapeutics seed track, available for therapeutics
start-ups. In addition, Cell BioEngines raised $0.25 million from
Empire State Development’s NY Ventures, the state’s venture capital
arm through the Pre-Seed and Seed Matching Fund Program.
“This reflects strong growth and investor
confidence in our innovative approach to advancing cell therapies,
particularly timely as we expand within New York State,” said Dr.
Ajay Vishwakarma, Founder and CEO.
“The funds will support our first multicenter
clinical trial, aimed at hematological cancer patients unable to
find a donor and seeking an alternative to HLA-haploidentical blood
stem cell transplants. CBE-101 represents a novel approach with
expanded cord blood-derived hematopoietic cell therapy, aligned
with Cell BioEngines' vision to deliver 'off-the-shelf' cell-based
therapies to patients”, he added.
About Cell BioEngines
Cell BioEngines, Inc., founded in Dec 2022, is a
clinical-stage biotech company focused on developing allogeneic
'off-the-shelf' stem cell-derived therapies as ‘drugs’ for human
disease treatment. The company leverages its proprietary platform
technology using universal 'non-gene-modified' donor blood stem
cells obtained from umbilical cord to produce clinical grade cells
at scale.
For more information about Cell BioEngines, and to learn more
the latest Company developments, please visit
www.cellbioengines.com
Contact
Mark Joubert., J.D. Chief Legal Officer Cell BioEngines, Inc
info@cellbioengines.com